Literature DB >> 33001842

SGLT2 Inhibitors across the Spectrum of Severity of CKD.

Ali Ziaolhagh1, Christos Argyropoulos2.   

Abstract

Entities:  

Keywords:  KDIGO risk category; SGLT2 inhibitors; chronic kidney disease; empaglflozin

Year:  2020        PMID： 33001842      PMCID： PMC7536745          DOI： 10.2215/CJN.13430820

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  9 in total

1.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine
Journal:  N Engl J Med       Date:  2018-11-10       Impact factor: 91.245

2.  Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.

Authors:  Christoph Wanner; Hiddo J L Heerspink; Bernard Zinman; Silvio E Inzucchi; Audrey Koitka-Weber; Michaela Mattheus; Stefan Hantel; Hans-Juergen Woerle; Uli C Broedl; Maximilian von Eynatten; Per-Henrik Groop
Journal:  J Am Soc Nephrol       Date:  2018-10-12       Impact factor: 10.121

3.  Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption.

Authors:  V Vallon; K Richter; R C Blantz; S Thomson; H Osswald
Journal:  J Am Soc Nephrol       Date:  1999-12       Impact factor: 10.121

4.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

5.  The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report.

Authors:  Andrew S Levey; Paul E de Jong; Josef Coresh; Meguid El Nahas; Brad C Astor; Kunihiro Matsushita; Ron T Gansevoort; Bertram L Kasiske; Kai-Uwe Eckardt
Journal:  Kidney Int       Date:  2010-12-08       Impact factor: 10.612

6.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

7.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Authors:  Vlado Perkovic; Meg J Jardine; Bruce Neal; Severine Bompoint; Hiddo J L Heerspink; David M Charytan; Robert Edwards; Rajiv Agarwal; George Bakris; Scott Bull; Christopher P Cannon; George Capuano; Pei-Ling Chu; Dick de Zeeuw; Tom Greene; Adeera Levin; Carol Pollock; David C Wheeler; Yshai Yavin; Hong Zhang; Bernard Zinman; Gary Meininger; Barry M Brenner; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2019-04-14       Impact factor: 91.245

8.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245

9.  Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial.

Authors:  Adeera Levin; Vlado Perkovic; David C Wheeler; Stefan Hantel; Jyothis T George; Maximilian von Eynatten; Audrey Koitka-Weber; Christoph Wanner
Journal:  Clin J Am Soc Nephrol       Date:  2020-09-29       Impact factor: 8.237
  9 in total
  1 in total

1.  Baseline Characteristics Associated With Sodium-Glucose Cotransporter Inhibitor Prescriptions in Type 2 Diabetic Patients in Jazan, Saudi Arabia.

Authors:  Mohammed Somaili; Omar Oraibi; Mostafa Mohrag; Abdelrahman Hommadi; Esam Moafa; Abdulrahman Kulaybi; Sahar Shobayli; Razan Moafa; Ghadah Mhgfory; Afaf Jaafari; Ayman Shami; Khalid Majrashi
Journal:  Cureus       Date:  2022-04-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.